ParenteralDosed ingredient Cosmetic cross-reference

Riboflavin

CAS 83-88-5

Riboflavin (CAS 83-88-5) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 4,115 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

4,115

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Riboflavin

CAS Number

83-88-5

UNII

TLM2976OFR

InChIKey

AUNGANRZJHBGPY-SCRDCRAPSA-N

ChEMBL ID

CHEMBL1534

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

Synonyms and normalized names

LACTOFLAVIN

dosed ingredientnatural productparenteral

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1534 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 8 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	22627.01607142857 nM	47	-
-	IC50	43243.89 nM	8	-
-	AC50	7949.5199999999995 nM	5	-
-	Kd	22.9 nM	4	-
-	Ki	350 nM	1	-
Flavin reductase (NADPH) Enzyme	-	-	-	Homo sapiens
Riboflavin kinase Kinase	-	-	-	Homo sapiens
Riboflavin-binding protein Unclassified	Kd	8.3	-	Gallus gallus

SOURCE DrugCentral 2023 / FAERS disproportionality 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pemphigus	5389	2650.244	10034280
Systemic lupus erythematosus	5715	2558.26	10042945
Glossodynia	4953	2239.129	10018388
Hand deformity	4328	1889.768	10061194
Arthropathy	5566	1758.989	10003285
Rheumatoid arthritis	5915	1728.096	10039073
Alopecia	6760	1671.808	10001760
Abdominal discomfort	6874	1609.454	10000059
Wound	4178	1535.289	10052428
Maternal exposure during pregnancy	4728	1481.572	10071408
Toxicity to various agents	995	1394.417	10070863
Completed suicide	162	1349.909	10010144
Synovitis	4239	1311.223	10042868
Joint swelling	6400	1218.955	10023232
Contraindicated product administered	4744	1192.649	10078504
Swelling	5520	1187.507	10042674
Anti-cyclic citrullinated peptide antibody positive	2939	1175.45	10068798
Discomfort	3821	1127.227	10013082
Pain	12110	1109.03	10033371
Pericarditis	3236	1102.796	10034484
Infusion related reaction	5355	1060.083	10051792
Drug abuse	120	927.034	10013654
Drug interaction	1462	868.073	10013710
Arthralgia	9622	865.263	10003239
Death	3378	861.559	10011906
Duodenal ulcer perforation	2092	743.624	10013849
Helicobacter infection	2160	719.03	10054263
Rheumatoid factor positive	1968	709.171	10039080
Psoriatic arthropathy	2235	670.781	10037162
Hepatic enzyme increased	3857	651.565	10060795
Exposure during pregnancy	2974	636.038	10073513
Musculoskeletal stiffness	3668	634.48	10052904
Drug intolerance	5259	608.444	10061822
Intentional overdose	116	599.969	10022523
Product use issue	4373	588.649	10076309
Acute kidney injury	2516	562.533	10069339
Febrile neutropenia	803	537.308	10016288
Therapeutic product effect decreased	3530	533.8	10082201
Overdose	675	442.031	10033295
Nasopharyngitis	4336	432.226	10028810
Knee arthroplasty	1264	393.046	10023469
Suicide attempt	157	384.931	10042464
Disease progression	882	379.538	10061818
Treatment failure	3524	375.958	10066901
Hypersensitivity	4562	372.569	10020751
Hip arthroplasty	1128	372.01	10020096
Impaired healing	1916	339.833	10021519
Foetal exposure during pregnancy	1806	331.388	10071404
Fatigue	12862	330.039	10016256
Rheumatic fever	970	327.192	10039054

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE RxNorm drug names 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
LACTOFLAVIN	9346	SU	MTHSPL
RIBOFLAVIN	9346	SU	MTHSPL
Riboflavin	9346	SU	MTHSPL
riboflavin	9346	IN	RXNORM
lactoflavin	9346	SY	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Riboflavin used for in pharmaceutical contexts?

Riboflavin (CAS 83-88-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Riboflavin?

Riboflavin has 4,115 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Glossodynia, Hand deformity, Arthropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Riboflavin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for RIBOFLAVIN with EU status "permitted".

What clinical phase is Riboflavin in?

Riboflavin is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Riboflavin?

Riboflavin has 8 bioactivity rows in this page query. Rendered target entries include Flavin reductase (NADPH), Riboflavin kinase, Riboflavin-binding protein.